Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Common Equity: 2022-2024

Historic Common Equity for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $757.5 million.

  • NewAmsterdam Pharma Co N.V's Common Equity rose 92.17% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $728.1 million, marking a year-over-year increase of 92.17%. This contributed to the annual value of $757.5 million for FY2024, which is 162.66% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Common Equity stood at $757.5 million for FY2024, which was up 162.66% from $288.4 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Common Equity peaked at $757.5 million during FY2024, and registered a low of $288.4 million during FY2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Common Equity had a median value of $430.1 million in 2022 and averaged $492.0 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Common Equity crashed by 32.94% in 2023 and then spiked by 162.66% in 2024.
  • Yearly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Common Equity stood at $430.1 million in 2022, then tumbled by 32.94% to $288.4 million in 2023, then skyrocketed by 162.66% to $757.5 million in 2024.